Evidence map›Paper›PMID 37675111›Full record

ArticleFrontiers in immunology2023

María García-Bengoa, Marita Meurer, Matthias Stehr, Ayssar A Elamin, Mahavir Singh, Wulf Oehlmann, Matthias Mörgelin, Maren von Köckritz-Blickwede

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

María García-BengoaInstitute of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Marita MeurerInstitute of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Matthias StehrLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Ayssar A ElaminLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Mahavir SinghLIONEX Diagnostics and Therapeutics GmbH, Braunschweig, Germany.
Wulf OehlmannUGA Biopharma GmbH, Hennigsdorf, Germany.
Matthias MörgelinColzyx AB, Lund, Sweden.
Maren von Köckritz-BlickwedeInstitute of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Lionex (Germany) · DEUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Neutrophil granulocytes predominate in the lungs of patients infected with Methods: Here, we investigated NET induction by PE18, PPE26, and PE31 in primary human blood-derived neutrophils. Neutrophils were stimulated with the respective proteins for 3h, and NET formation was subsequently assessed using confocal fluorescence microscopy. Intracellular ROS levels and cell necrosis were estimated by flow cytometry. Additionally, the influence of phorbol-12-myristate-13-acetate (PMA), a known NADPH oxidase enhancer, on NET formation was examined. Neutrophil integrity following incubation with the PE/PPE proteins was evaluated using transmission electron microscopy. Results: For the first time, we report that stimulation of primary human blood-derived neutrophils with Discussion: These findings offer valuable insights that contribute to a better understanding of host-pathogen interactions during

Indexed as

Extracellular TrapsMycobacterium tuberculosisGlutamic AcidHumansNeutrophilsReactive Oxygen SpeciesGlutamic AcidReactive Oxygen SpeciesMtbMycobacterium tuberculosisneutrophil extracellular traps (NETs)PE18PE31PPE26reactive oxygen speciestherapeutics

Identifiers

PMID37675111
PMCPMC10478095
OpenAlexW4386073917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.